Incorporating lower grade toxicity information into dose finding designs

Clinical Trials

Volumn 8, Issue 4, 2011, Pages 370-379

  Iasonos, Alexia ^a   Zohar, Sarah ^b   O'Quigley, John ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; CONTINUAL REASSESSMENT METHOD; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG INFORMATION; DRUG TOXICITY; DRUG TOXICITY GRADE; INTERMETHOD COMPARISON; MAXIMUM TOLERATED DOSE; METHODOLOGY; MODEL; PRIORITY JOURNAL; PROBABILITY; SCORING SYSTEM; SIMULATION;

CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; HUMANS; MAXIMUM TOLERATED DOSE; RESEARCH DESIGN; TOXICITY TESTS;

EID: 80051688021     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774511410732     Document Type: Article

References (23)

1. Common Terminology Criteria for Adverse Events, Version 4.0, DCTD, NCI, NIH, DHHS. August, 2010 (http://ctep.cancer.gov).
2. Rogatko A, Schoeneck D, Jonas W, et al. Translation of innovative designs into phase I trials. J Clin Oncol. 2007 ; 25: 4982-86 (Pubitemid 350220431)
3. Ivanova A, Kim SH. Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach. Biometrics. 2009 ; 65: 307-15
4. Yuan Z, Chappell R, Bailey H. The continual reassessment method for toxicity grades: a Bayesian quasi-likelihood approach. Biometrics. 2007 ; 63: 173-79
5. Ivanova A. Escalation, group and A + B designs for dose-finding trials. Stat Med. 2006 ; 25: 3668-78 (Pubitemid 44613901)
6. Van Meter EM, Garrett-Mayer E, Bandyopadhyay D. Proportional odds model for dose finding clinical trial designs with ordinal response. Stat Med 2011. Published online. doi: 10.1002/sim.4069. :
7. Paul RK, Rosenberger WF, Flournoy N. Quantile estimation following non-parametric Phase I clincial trials with ordinal response. Stat Med. 2004 ; 23: 2483-95 (Pubitemid 39149262)
8. Bekele NB, Thall FP. Dose-finding based on multiple toxicities in a soft tissue sarcoma trial. J Am Stat Assoc. 2004 ; 99: 26-35
9. Chen Z, Tighiouart M, Krailo MD, Azen SP 2010, Abstract 18. Baltimore, Maryland, USA :
10. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med. 1999 ; 17: 1103-120
11. Lee SM, Cheng B, Cheung YK. Continual reassessment method with multiple toxicity constraints. Biostatistics. 2010 ; 1: 13-13
12. Wang C, Chen TT, Tyan I. Designs for phase I cancer clinical trials with differentiation of graded toxicity. Commun Statist Theory Methods. 2000 ; 29: 975-87
13. Ivanova A, Murphy M. An adaptive first in man dose-escalation study of NGX267: statistical, clinical, and operational considerations. J Biopharm Statist. 2009 ; 19: 247-55
14. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics. 1990 ; 46: 33-48 (Pubitemid 20245604)
15. O'Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics. 1996 ; 52: 673-84 (Pubitemid 26187071)
16. Iasonos A, Wilton AS, Riedel ER, et al. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in phase I dose-finding studies. Clin Trials. 2008 ; 5: 465-77
17. Moller S. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat Med. 1995 ; 14: 911-22
18. O'Quigley J. Theoretical study of the continual reassessment method. J Statist Plann Infer. 2006 ; 136: 1765-80 (Pubitemid 43193548)
19. Cheung YK. Coherence principles in dose-finding studies. Biometrika. 2005 ; 92: 863:873-863:873
20. O'Quigley J. Continual reassessment designs with early termination. Biostatistics. 2002 ; 3: 87-99
21. O'Quigley J, Zohar S. Experimental designs for phase I and phase I/II dose-finding studies. Br J Cancer. 2006 ; 94: 609-13 (Pubitemid 43361888)
22. O'Quigley J, Paoletti X, Maccario J. Non-parametric optimal design in dose finding studies. Biostatistics. 2002 ; 3: 51-6 (Pubitemid 34374242)
23. O'Quigley J, Reiner E. A stopping rule for the continual reassessment method. Biometrika. 1998 ; 85: 741-48